Kakar SS and Jennes L: Expression of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor mRNAs in various non-reproductive human tissues. Cancer Lett. 98:57–62. 1995. View Article : Google Scholar : PubMed/NCBI

Liu F, Usui I, Evans LG, Austin DA, Mellon PL, Olefsky JM and Webster NJ: Involvement of both G(q/11) and G(s) proteins in gonadotropin-releasing hormone receptor-mediated signaling in L beta T2 cells. J Biol Chem. 277:32099–32108. 2002. View Article : Google Scholar : PubMed/NCBI

Hamm HE: How activated receptors couple to G proteins. Proc Natl Acad Sci USA. 98:4819–4821. 2001. View Article : Google Scholar : PubMed/NCBI

Gilman AG: G proteins: Transducers of receptor-generated signals. Annu Rev Biochem. 56:615–649. 1987. View Article : Google Scholar : PubMed/NCBI

Ford CE, Skiba NP, Bae H, Daaka Y, Reuveny E, Shekter LR, Rosal R, Weng G, Yang CS, Iyengar R, et al: Molecular basis for interactions of G protein betagamma subunits with effectors. Science. 280:1271–1274. 1998. View Article : Google Scholar : PubMed/NCBI

Berridge MJ and Irvine RF: Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature. 312:315–321. 1984. View Article : Google Scholar : PubMed/NCBI

Limor R, Ayalon D, Capponi AM, Childs GV and Naor Z: Cytosolic free calcium levels in cultured pituitary cells separated by centrifugal elutriation: Effect of gonadotropin-releasing hormone. Endocrinology. 120:497–503. 1987. View Article : Google Scholar : PubMed/NCBI

Tse FW, Tse A, Hille B, Hille B, Horstmann H and Almers W: Local Ca²⁺ release from internal stores controls exocytosis in pituitary gonadotrophs. Neuron. 18:121–132. 1997. View Article : Google Scholar : PubMed/NCBI

Naor Z, Harris D and Shacham S: Mechanism of GnRH receptor signaling: Combinatorial cross-talk of Ca²⁺ and protein kinase C. Front Neuroendocrinol. 19:1–19. 1998. View Article : Google Scholar : PubMed/NCBI

Kim Y, Han JM, Park JB, Lee SD, Oh YS, Chung C, Lee TG, Kim JH, Park SK, Yoo JS, et al: Phosphorylation and activation of phospholipase D1 by protein kinase C in vivo: Determination of multiple phosphorylation sites. Biochemistry. 38:10344–10351. 1999. View Article : Google Scholar : PubMed/NCBI

Mitchell R, Robertson DN, Holland PJ, Collins D, Lutz EM and Johnson MS: ADP-ribosylation factor-dependent phospholipase D activation by the M3 muscarinic receptor. J Biol Chem. 278:33818–33830. 2003. View Article : Google Scholar : PubMed/NCBI

Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H, Finkenzeller G, Marmé D and Rapp UR: Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature. 364:249–252. 1993. View Article : Google Scholar : PubMed/NCBI

Levi NL, Hanoch T, Benard O, Rozenblat M, Harris D, Reiss N, Naor Z and Seger R: Stimulation of Jun N-terminal kinase (JNK) by gonadotropin-releasing hormone in pituitary alpha T3-1 cell line is mediated by protein kinase C, c-Src, and CDC42. Mol Endocrinol. 12:815–824. 1998.PubMed/NCBI

Mulvaney JM and Roberson MS: Divergent signaling pathways requiring discrete calcium signals mediate concurrent activation of two mitogen-activated protein kinases by gonadotropin-releasing hormone. J Biol Chem. 275:14182–14189. 2000. View Article : Google Scholar : PubMed/NCBI

Seger R and Krebs EG: The MAPK signaling cascade. FASEB J. 9:726–735. 1995.PubMed/NCBI

Maurer RA, Kim KE, Schoderbek WE, Roberson MS and Glenn DJ and Glenn DJ: Regulation of glycoprotein hormone alpha-subunit gene expression. Recent Prog Horm Res. 54:455–484; discussion 485. 1999.PubMed/NCBI

Ben-Menahem D, Shraga-Levine Z, Limor R and Naor Z: Arachidonic acid and lipoxygenase products stimulate gonadotropin alpha-subunit mRNA levels in pituitary alpha T3-1 cell line: Role in gonadotropin releasing hormone action. Biochemistry. 33:12795–12799. 1994. View Article : Google Scholar : PubMed/NCBI

Shraga-Levine Z, Ben-Menahem D and Naor Z: Arachidonic acid and lipoxygenase products stimulate protein kinase C beta mRNA levels in pituitary alpha T3-1 cell line: Role in gonadotropin-releasing hormone action. Biochem J. 316:667–670. 1996. View Article : Google Scholar : PubMed/NCBI

Bliss SP, Navratil AM, Xie J and Roberson MS: GnRH signaling, the gonadotrope and endocrine control of fertility. Front Neuroendocrinol. 31:322–340. 2010. View Article : Google Scholar : PubMed/NCBI

Miller RS, Wolfe A, He L, Radovick S and Wondisford FE: CREB binding protein (CBP) activation is required for luteinizing hormone beta expression and normal fertility in mice. Mol Cell Biol. 32:2349–2358. 2012. View Article : Google Scholar : PubMed/NCBI

Khadra A and Li YX: A model for the pulsatile secretion of gonadotropin-releasing hormone from synchronized hypothalamic neurons. Biophys J. 91:74–83. 2006. View Article : Google Scholar : PubMed/NCBI

Haisenleder DJ, Dalkin AC, Ortolano GA, Marshall JC and Shupnik MA: A pulsatile gonadotropin-releasing hormone stimulus is required to increase transcription of the gonadotropin subunit genes: Evidence for differential regulation of transcription by pulse frequency in vivo. Endocrinology. 128:509–517. 1991. View Article : Google Scholar : PubMed/NCBI

Qayum A, Gullick W, Clayton RC, Sikora K and Waxman J and Waxman J: The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer. 62:96–99. 1990. View Article : Google Scholar : PubMed/NCBI

Halmos G, Arencibia JM, Schally AV, Davis R and Bostwick DG: High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol. 163:623–629. 2000. View Article : Google Scholar : PubMed/NCBI

Fekete M, Redding TW, Comaru-Schally AM, Pontes JE, Connelly RW, Srkalovic G and Schally AV: Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia. Prostate. 14:191–208. 1989. View Article : Google Scholar : PubMed/NCBI

Limonta P, Dondi D, Moretti RM, Maggi R and Motta M: Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab. 75:207–212. 1992.PubMed/NCBI

Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E and Motta M: Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: Evidence for an autocrine-inhibitory LHRH loop. Cancer Res. 54:4091–4095. 1994.PubMed/NCBI

Redding TW and Schally AV: Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA. 78:6509–6512. 1981. View Article : Google Scholar : PubMed/NCBI

Tolis G, Ackman D, Stellos A, Mehta A, Labrie F, Fazekas AT, Comaru-Schally AM and Schally AV: Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci USA. 79:1658–1662. 1982. View Article : Google Scholar : PubMed/NCBI

Koppán M, Nagy A, Schally AV, Plonowski A, Halmos G, Arencibia JM and Groot K: Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice. Prostate. 38:151–158. 1999. View Article : Google Scholar : PubMed/NCBI

Arencibia JM, Schally AV, Halmos G, Nagy A, Kiaris H and Klaris H: In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses. Anticancer Drugs. 12:71–78. 2001. View Article : Google Scholar : PubMed/NCBI

Gnanapragasam VJ, Darby S, Khan MM, Lock WG, Robson CN and Leung HY and Leung HY: Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer. J Pathol. 206:205–213. 2005. View Article : Google Scholar : PubMed/NCBI

Gründker C, Huschmand Nia A and Emons G: Gonadotropin-releasing hormone receptor-targeted gene therapy of gynecologic cancers. Mol Cancer Ther. 4:225–231. 2005.PubMed/NCBI

Limonta P, Dondi D, Moretti RM, Fermo D, Garattini E and Motta M: Expression of luteinizing hormone-releasing hormone mRNA in the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab. 76:797–800. 1993.PubMed/NCBI

Moretti RM, Marelli MM, Dondi D, Poletti A, Martini L, Motta M and Limonta P: Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. J Clin Endocrinol Metab. 81:3930–3937. 1996.PubMed/NCBI

Marelli MM, Moretti RM, Dondi D, Motta M and Limonta P: Luteinizing hormone-releasing hormone agonists interfere with the mitogenic activity of the insulin-like growth factor system in androgen-independent prostate cancer cells. Endocrinology. 140:329–334. 1999.PubMed/NCBI

Maudsley S, Davidson L, Pawson AJ, Chan R, López de Maturana R and Millar RP: Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor. Cancer Res. 64:7533–7544. 2004. View Article : Google Scholar : PubMed/NCBI

Kraus S, Levy G, Hanoch T, Naor Z and Seger R: Gonadotropin-releasing hormone induces apoptosis of prostate cancer cells: Role of c-Jun NH2-terminal kinase, protein kinase B, and extracellular signal-regulated kinase pathways. Cancer Res. 64:5736–5744. 2004. View Article : Google Scholar : PubMed/NCBI

Kraus S, Naor Z and Seger R: Gonadotropin-releasing hormone in apoptosis of prostate cancer cells. Cancer Lett. 234:109–123. 2006. View Article : Google Scholar : PubMed/NCBI

Choi JH, Gilks CB, Auersperg N and Leung PC: Immuno-localization of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and type I GnRH receptor during follicular development in the human ovary. J Clin Endocrinol Metab. 91:4562–4570. 2006. View Article : Google Scholar : PubMed/NCBI

Emons G, Ortmann O, Schulz KD and Schally AV: Growth-inhibitory actions of analogues of Luteinizing hormone releasing hormone on tumor cells. Trends Endocrinol Metab. 8:355–362. 1997. View Article : Google Scholar

Völker P, Gründker C, Schmidt O, Schulz KD and Emons G: Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: Frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am J Obstet Gynecol. 186:171–179. 2002. View Article : Google Scholar : PubMed/NCBI

Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Hölzel F, Schulz KD and Schally AV: High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res. 53:5439–5446. 1993.PubMed/NCBI

Yano T, Pinski J, Halmos G, Szepeshazi K, Groot K and Schally AV: Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci USA. 91:7090–7094. 1994. View Article : Google Scholar : PubMed/NCBI

So WK, Cheng JC, Poon SL and Leung PC: Gonadotropin-releasing hormone and ovarian cancer: A functional and mechanistic overview. FEBS J. 275:5496–5511. 2008. View Article : Google Scholar : PubMed/NCBI

Wilkinson SJ, Kucukmetin A, Cross P, Darby S, Gnanapragasam VJ, Calvert AH, Robson CN and Edmondson RJ: Expression of gonadotrophin releasing hormone receptor I is a favorable prognostic factor in epithelial ovarian cancer. Hum Pathol. 39:1197–1204. 2008. View Article : Google Scholar : PubMed/NCBI

Imai A, Ohno T, Furui T, Takahashi K, Matsuda T and Tamaya T: Gonadotropin-releasing hormone stimulates phospholipase C but not protein phosphorylation/dephosphorylation in plasma membrane from human epithelial ovarian cancer. Int J Gynecol Cancer. 3:311–317. 1993. View Article : Google Scholar : PubMed/NCBI

Shibata S, Sato H, Ota H, Karube A, Takahashi O and Tanaka T: Involvement of annexin V in antiproliferative effects of gonadotropin-releasing hormone agonists on human endometrial cancer cell line. Gynecol Oncol. 66:217–221. 1997. View Article : Google Scholar : PubMed/NCBI

Kim KY, Choi KC, Auersperg N and Leung PC: Mechanism of gonadotropin-releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: Role of the GnRH-I receptor and protein kinase C pathway. Endocr Relat Cancer. 13:211–220. 2006. View Article : Google Scholar : PubMed/NCBI

Kimura A, Ohmichi M, Kurachi H, Ikegami H, Hayakawa J, Tasaka K, Kanda Y, Nishio Y, Jikihara H, Matsuura N, et al: Role of mitogen-activated protein kinase/extracellular signal-regulated kinase cascade in gonadotropin-releasing hormone-induced growth inhibition of a human ovarian cancer cell line. Cancer Res. 59:5133–5142. 1999.PubMed/NCBI

Imai A, Takagi H, Horibe S, Fuseya T and Tamaya T and Tamaya T: Coupling of gonadotropin-releasing hormone receptor to Gi protein in human reproductive tract tumors. J Clin Endocrinol Metab. 81:3249–3253. 1996.PubMed/NCBI

Imai A, Horibe S, Takagi A and Tamaya T: Gi protein activation of gonadotropin-releasing hormone-mediated protein dephosphorylation in human endometrial carcinoma. Am J Obstet Gynecol. 176:371–376. 1997. View Article : Google Scholar : PubMed/NCBI

Emons G, Muller V, Ortmann O, Grossmann G, Trautner U, Stuckrad B, Schulz K and Schally A: Luteinizing hormone-releasing hormone agonist triptorelin antagonizes signal transduction and mitogenic activity of epidermal growth factor in human ovarian and endometrial cancer cell lines. Int J Oncol. 9:1129–1137. 1996.PubMed/NCBI

Gründker C, Völker P and Emons G: Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase. Endocrinology. 142:2369–2380. 2001.PubMed/NCBI

Shirahige Y, Cook C, Pinski J, Halmos G, Nair R and Schally A: Treatment with luteinizing-hormone-releasing hormone antagonist sb-75 decreases levels of epidermal growth-factor receptor and its messenger-RNA in ov-1063 human epithelial ovarian-cancer xenografts in nude-mice. Int J Oncol. 5:1031–1035. 1994.PubMed/NCBI

Cho-Clark M, Larco DO, Semsarzadeh NN, Vasta F, Mani SK and Wu TJ: GnRH-(1–5) transactivates EGFR in Ishikawa human endometrial cells via an orphan G protein-coupled receptor. Mol Endocrinol. 28:80–98. 2014. View Article : Google Scholar

Szabó I, Bősze S, Orbán E, Sipos É, Halmos G, Kovács M and Mező G: Comparative in vitro biological evaluation of daunorubicin containing GnRH-I and GnRH-II conjugates developed for tumor targeting. J Pept Sci. 21:426–435. 2015. View Article : Google Scholar : PubMed/NCBI

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM and Nielsen TO: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 14:1368–1376. 2008. View Article : Google Scholar : PubMed/NCBI

Gründker C, Föst C, Fister S, Nolte N, Günthert AR and Emons G: Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo. Breast Cancer Res. 12:R492010. View Article : Google Scholar : PubMed/NCBI

Sedgley KR, Finch AR, Caunt CJ and McArdle CA: Intracellular gonadotropin-releasing hormone receptors in breast cancer and gonadotrope lineage cells. J Endocrinol. 191:625–636. 2006. View Article : Google Scholar : PubMed/NCBI

Limonta P, Montagnani Marelli M, Mai S, Motta M, Martini L and Moretti RM: GnRH receptors in cancer: From cell biology to novel targeted therapeutic strategies. Endocr Rev. 33:784–811. 2012. View Article : Google Scholar : PubMed/NCBI

Fekete M, Wittliff JL and Schally AV: Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal. 3:137–147. 1989. View Article : Google Scholar

Baumann KH, Kiesel L, Kaufmann M, Bastert G and Runnebaum B: Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters. Breast Cancer Res Treat. 25:37–46. 1993. View Article : Google Scholar : PubMed/NCBI

Moriya T, Suzuki T, Pilichowska M, Ariga N, Kimura N, Ouchi N, Nagura H and Sasano H: Immunohistochemical expression of gonadotropin releasing hormone receptor in human breast carcinoma. Pathol Int. 51:333–337. 2001. View Article : Google Scholar : PubMed/NCBI

Mangia A, Tommasi S, Reshkin SJ, Simone G, Stea B, Schittulli F and Paradiso A: Gonadotropin releasing hormone receptor expression in primary breast cancer: Comparison of immunohistochemical, radioligand and Western blot analyses. Oncol Rep. 9:1127–1132. 2002.PubMed/NCBI

Morgan K, Meyer C, Miller N, Sims AH, Cagnan I, Faratian D, Harrison DJ, Millar RP and Langdon SP: GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines. BMC Cancer. 11:4762011. View Article : Google Scholar : PubMed/NCBI

Millar RP, Pawson AJ, Morgan K, Rissman EF and Lu ZL: Diversity of actions of GnRHs mediated by ligand-induced selective signaling. Front Neuroendocrinol. 29:17–35. 2008. View Article : Google Scholar

Naor Z and Huhtaniemi I: Interactions of the GnRH receptor with heterotrimeric G proteins. Front Neuroendocrinol. 34:88–94. 2013. View Article : Google Scholar

Sviridonov L, Dobkin-Bekman M, Shterntal B, Przedecki F, Formishell L, Kravchook S, Rahamim-Ben Navi L, Bar-Lev TH, Kazanietz MG, Yao Z, et al: Differential signaling of the GnRH receptor in pituitary gonadotrope cell lines and prostate cancer cell lines. Mol Cell Endocrinol. 369:107–118. 2013. View Article : Google Scholar : PubMed/NCBI

Aguila r-Rojas A, Huer ta-Reyes M, Maya-Núñez G, Arechavaleta-Velásco F, Conn PM, Ulloa-Aguirre A and Valdés J: Gonadotropin-releasing hormone receptor activates GTPase RhoA and inhibits cell invasion in the breast cancer cell line MDA-MB-231. BMC Cancer. 12:5502012. View Article : Google Scholar

Goodson AG and Grossman D: Strategies for early melanoma detection: Approaches to the patient with nevi. J Am Acad Dermatol. 60:719–735; quiz 736–718. 2009. View Article : Google Scholar : PubMed/NCBI

Moretti RM, Mai S, Montagnani Marelli M, Bani MR, Ghilardi C, Giavazzi R, Taylor DM, Martini PG and Limonta P: Dual targeting of tumor and endothelial cells by gonadotropin-releasing hormone agonists to reduce melanoma angiogenesis. Endocrinology. 151:4643–4653. 2010. View Article : Google Scholar : PubMed/NCBI

Wen J, Feng Y, Bjorklund CC, Wang M, Orlowski RZ, Shi ZZ, Liao B, O'Hare J, Zu Y, Schally AV, et al: Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo. Mol Cancer Ther. 10:148–158. 2011. View Article : Google Scholar

Ghiringhelli F, Isambert N and Ladoire S: Degarelix as a new antiangiogenic agent for metastatic colon cancer? World J Gastroenterol. 19:769–772. 2013. View Article : Google Scholar : PubMed/NCBI

Schreier VN, Pethő L, Orbán E, Marquardt A, Petre BA, Mező G and Manea M: Protein expression profile of HT-29 human colon cancer cells after treatment with a cytotoxic daunorubicin-GnRH-III derivative bioconjugate. PLoS One. 9:e940412014. View Article : Google Scholar : PubMed/NCBI

Carlson MJ, Thiel KW and Leslie KK: Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int J Womens Health. 6:429–435. 2014.PubMed/NCBI

Zhang J, Chtcheglova LA, Zhu R, Hinterdorfer P, Zhang B and Tang J: Nanoscale organization of human GnRH-R on human bladder cancer cells. Anal Chem. 86:2458–2464. 2014. View Article : Google Scholar : PubMed/NCBI

Conn PM, Janovick JA, Brothers SP and Knollman PE: ‘Effective inefficiency’: Cellular control of protein trafficking as a mechanism of post-translational regulation. J Endocrinol. 190:13–16. 2006. View Article : Google Scholar : PubMed/NCBI

Maya-Núñez G, Janovick JA and Conn PM: Combined modification of intracellular and extracellular loci on human gonadotropin-releasing hormone receptor provides a mechanism for enhanced expression. Endocrine. 13:401–407. 2000. View Article : Google Scholar

Conn PM and Janovick JA: Drug development and the cellular quality control system. Trends Pharmacol Sci. 30:228–233. 2009. View Article : Google Scholar : PubMed/NCBI

Janovick JA, Patny A, Mosley R, Goulet MT, Altman MD, Rush TS III, Cornea A and Conn PM: Molecular mechanism of action of pharmacoperone rescue of misrouted GPCR mutants: The GnRH receptor. Mol Endocrinol. 23:157–168. 2009. View Article : Google Scholar :

Maya-Núñez G, Ulloa-Aguirre A, Janovick JA and Conn PM: Pharmacological chaperones correct misfolded GPCRs and rescue function: Protein trafficking as a therapeutic target. Subcell Biochem. 63:263–289. 2012. View Article : Google Scholar : PubMed/NCBI

Maya-Núñez G, Janovick JA, Ulloa-Aguirre A, Söderlund D, Conn PM and Méndez JP: Molecular basis of hypogonadotropic hypogonadism: Restoration of mutant (E(90)K) GnRH receptor function by a deletion at a distant site. J Clin Endocrinol Metab. 87:2144–2149. 2002. View Article : Google Scholar : PubMed/NCBI

Janovick JA, Maya-Nunez G and Conn PM: Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: Misrouted proteins as a novel disease etiology and therapeutic target. J Clin Endocrinol Metab. 87:3255–3262. 2002. View Article : Google Scholar : PubMed/NCBI

Conn PM and Ulloa-Aguirre A: Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptors. Adv Pharmacol. 62:109–141. 2011. View Article : Google Scholar : PubMed/NCBI

Janovick JA, Knollman PE, Brothers SP, Ayala-Yáñez R, Aziz AS and Conn PM: Regulation of G protein-coupled receptor trafficking by inefficient plasma membrane expression: Molecular basis of an evolved strategy. J Biol Chem. 281:8417–8425. 2006. View Article : Google Scholar : PubMed/NCBI

Cheung LW and Wong AS: Gonadotropin-releasing hormone: GnRH receptor signaling in extrapituitary tissues. FEBS J. 275:5479–5495. 2008. View Article : Google Scholar : PubMed/NCBI

Sánchez CA, Mercado AJ, Contreras HR, Cabezas JC, Huidobro CC and Castellón EA: Pharmacoperone IN3 enhances the apoptotic effect of leuprolide in prostate cancer cells by increasing the gonadotropin-releasing hormone receptor in the cell membrane. Anticancer Drugs. 23:959–969. 2012.PubMed/NCBI

Fister S, Günthert AR, Aicher B, Paulini KW, Emons G and Gründker C: GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax. Cancer Res. 69:6473–6481. 2009. View Article : Google Scholar : PubMed/NCBI

Cheng CK and Leung PC: Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. Endocr Rev. 26:283–306. 2005. View Article : Google Scholar

Janovick JA, Stewart MD, Jacob D, Martin LD, Deng JM, Stewart CA, Wang Y, Cornea A, Chavali L, Lopez S, et al: Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy. Proc Natl Acad Sci USA. 110:21030–21035. 2013. View Article : Google Scholar : PubMed/NCBI